Standard-of-care Systemic Therapy With or Without Local Therapy in Patients With Oligoprogressive Non-Small Cell Lung Cancer(NSCLC）

Phase 2/3 Active not recruiting 97 enrolled Shanghai Chest Hospital

RandomizedParallel-groupOpen-labelTreatment

Summary

This is a randomized, controlled, phase II/III clinical study to evaluate the efficacy and safety of stand-of-care systemic therapy with local therapy versus stand-of-care systemic therapy in patients with oligoprogressive non-small cell lung cancer(NSCLC).

Timeline

Start: 2025-06-03
Primary completion: 2028-05-31
Completion: 2028-05-31

Drugs

Evaluation	Drug	Modality	Dose	Route
Background	Docetaxel	Small molecule	—	—
Background	Ivonescimab	Monoclonal antibody	—	—
Background	Pemetrexed	Small molecule	—	—
Background	Sintilimab	Monoclonal antibody	—	—

Standard-of-care Systemic Therapy With or Without Local Therapy in Patients With Oligoprogressive Non-Small Cell Lung Cancer(NSCLC）

Summary

Timeline

Drugs

Indications